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Background: Cutaneous analgesia for venepuncture pain can be achieved using various topically applied local anaesthetic 
formulations. Xylocaine® 10% Pump Spray containing lignocaine hydrochloride and 95% ethanol is exclusively recommended 
for mucosal anaesthesia. However, this formulation is readily able to penetrate skin. This study investigated whether topical pre-
treatment with Xylocaine® 10% Pump Spray could facilitate analgesia for venepuncture.
Methods: A single-centre, prospective, randomised, double-blind placebo-controlled trial was conducted. One hundred patients 
were enrolled. The control and intervention groups had 0.5 ml saline and 0.5 ml Xylocaine® applied for 20 min to preselected 
venepuncture sites. Pain associated with an 18-gauge cannula venepuncture was rated on an 11-point Numerical Rating Scale. 
A two-point or 30% reduction in pain would be deemed clinically significant.
Results: Pain scores were lower (p = 0.001) in the Xylocaine® (median 2; 95% CI 2–3) than the saline (median 4; 95% CI 3–5) group. 
Moderate-to-severe pain occurred in fewer Xylocaine® (18%) than saline (42%) treated patients (relative risk 0.43, CI 0.22 to 0.48; 
NNT = 5).
Conclusion: Topical Xylocaine® 10% Pump Spray pre-treatment provided a time-effective method of reducing venepuncture-
associated pain.
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Introduction
A patient’s only clear recollection of the anaesthetic process may 
be the pre-induction, painful, venous cannulation. Ameliorating 
venepuncture-related pain may greatly improve a patient’s 
rating of his/her anaesthetic experience.1
Previous research has indicated that topical Xylocaine® Pump 
Spray effected sufficient skin anaesthesia to increase the 
threshold for the perception of electrical current,2 and that it 
significantly decreased pain perception during burns dressing 
changes when applied to the broken skin of the graft donor site.3 
We investigated whether Xylocaine® 10% Pump Spray could 
efficiently provide sufficient cutaneous analgesia to reduce 
venepuncture-related pain. A standard dose of Xylocaine® Pump 
Spray was sprayed onto a 2 cm square gauze pad. This gauze pad 
was affixed to the skin over the intended venepuncture site 
using a translucent, adhesive dressing.
Kanai et al. observed an increase in skin electrical current 
perception threshold after only a 30-min application of either 
lignocaine spray or lignocaine emulsion. While this study 
reported faster onset of cutaneous ‘analgesia’ with lignocaine 
spray than with the lignocaine emulsion,2 we cannot identify 
previous research investigating Xylocaine® Pump Spray to 
ameliorate venepuncture pain. Based on the research of Kanai et 
al.2 and a small pilot study we conducted, we decided to 
investigate the effectiveness of a 20-min application time.
Methods
A single-centre, prospective, randomised, double-blind, placebo-
controlled trial was conducted. University Human Research 
Ethics Committee approval was obtained. Eligible patients 
provided prior, written, informed consent. Inclusion criteria 
comprised a minimum age of 18 years, elective surgery, pregnant 
patients greater than 38  weeks’ gestation presenting for 
Caesarean section, and patients who did not already have an 
appropriate size, satisfactorily functioning intravenous cannula 
sited before arrival in theatre. Exclusion criteria included females 
of childbearing age in whom early pregnancy had not been 
excluded, decreased level of consciousness or neurological 
deficit (rendering a patient incapable of performing the pain 
score reliably), broken skin over the proposed venepuncture site, 
patients having received sedation or analgesia within the last 12 
h, and/or a history of adverse reactions to lignocaine.
Patients were randomised into two groups: group X who received 
the treatment (Xylocaine® 10% Pump Spray, AstraZeneca, North 
Ryde, NSW), and group S who received the normal saline placebo. 
A numbered computer-generated randomisation sheet was 
used.4 The two investigators were blinded to group allocations.
One of the two investigators identified and marked an 
appropriate forearm vein and venepuncture site between the 
elbow and the hand. The venepuncture site was prepared using 
a 70% isopropyl alcohol-soaked wipe (Webcol™, Covidien, 
Dublin, Ireland). Only the anaesthesia assistant was unblinded to 
the patient group allocation. This assistant impregnated a 2-cm 
square, double-layered piece of gauze with either five pumps of 
Xylocaine® Spray or 0.5 ml of sterile, normal saline. The 0.5 ml of 
a 10% solution contains 50 mg lignocaine. This piece of gauze 
was applied to the venepuncture site using an occlusive, 
transparent dressing (Opsite Flexigrid®, Smith & Nephew, 
London, UK). After a 20-min application time, the dressing was 
removed by one of the two investigators and an 18-gauge 
cannula (B|Braun Vasofix® Safety, Melsungen, Germany) was 
sited.
The investigator then requested the patient to rate needle 
insertion related pain using an 11-point, 0–10, Numerical Rating 
Scale. The Numerical Rating Scale was chosen due to its ease of 
interpretation for patients and its usefulness in both literate and 
illiterate patients.5 Numerical rating scale anchors were no pain 
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(0) and most severe pain imaginable (10). If the initial attempt 
failed, the patient was asked to complete the score for the 
attempted venepuncture before the second attempt was made. 
Second attempts were not scored.
We decided beforehand that a clinically significant reduction in 
pain would be indicated by a two-point decrease in the 11-point 
numerical rating pain scale.
A power calculation using PASS version 12 (Hintze, J. 2013. PASS 
12. NCSS, LLC. Kaysville, Utah, USA; www.ncss.com), revealed 
that 42 individuals per group would be needed to detect a two-
point difference (standard deviation 2.8) with alpha 0.05 and 
power 90%. We decided to study 50 patients per group.6
SPSS® version 22 (IBM Corp. Released 2013. IBM SPSS Statistics for 
Windows. Version 22.0, IBM Corp, Armonk, NY, USA) was used for 
data analysis. The 95% confidence intervals (95% CI) and number 
needed to treat for non-parametric data were calculated using 
EpiCalc version 1.02 (Gilman, J. and Myatt, M. (1998), EpiCalc 2000 
1.02). Demographics and baseline outcomes were compared 
between the two groups using chi-square tests for categorical 
variables and Student’s t-tests for continuous, normally distributed 
variables. Pain scores and further ordinal data were compared 
using non-parametric Mann Whitney U-tests. Numerical Rating 
Scale pain scores were categorised as mild (1–4), moderate (5–7), 
and severe (8–10).7 We also dichotomised pain outcomes into ‘nil-
to-mild’ (Numerical Rating Scale 0–4) and ‘moderate-to-severe’ 
(Numerical Rating Scale 5–10) groups. A p-value of < 0.05 was 
considered statistically significant. We considered clinical 
significance as being a two-point or 30% reduction in pain scores. 
Parametric data are presented as mean, standard deviation (SD) 
and 95% confidence intervals. Non-parametric data are presented 
as median, interquartile ranges (IQR) and 95% CI.
Results
One hundred patients participated in the study. No between-
group demographic differences were identified (Table 1). No 
adverse reactions or Xylocaine® spray related skin changes were 
observed.
Median pain scores were reduced from 4 to 2 (p = 0.001) in 
groups S and X respectively (Table 2 and Figure 1).
No between-group differences in age or gender were identified.
The median pain score was reduced from 4 in the saline group 
(Group S) to 2 in the Xylocaine® group (Group X).
Pain scores were lower in the intervention group (p = 0.006), 
being rated as absent (20% vs. 4%), mild (62% vs. 54%), moderate 
(18% vs. 32%), and severe (0 vs. 10%) in the X and S groups 
(Figure 2).
Dichotomisation revealed a higher incidence of ‘nil-to-mild’ (82% 
vs. 58%) than ‘moderate-to-severe’ (18% vs. 42%) venepuncture-
related pain (p = 0.009) in group X than in group S (Figure 3). 
Xylocaine® venepuncture site pre-treatment reduced the risk of 
‘moderate-to- severe’ pain by 57% (risk ratio 0.43; 95% CI 0.22–
0.48). The number needed to treat (NNT) to decrease pain from 
the ‘moderate-to-severe’ to ‘nil-to-mild group’ was 5.
Discussion
We hypothesised that a 20 min application of Xylocaine® 10% 
Pump Spray would ameliorate venepuncture pain compared 
with a placebo. We observed a statistically and clinically 
significant reduction in pain scores compared with the placebo. 
A NNT of 5 was required to shift pain from the ‘moderate-to-
severe’ to ‘nil-to-mild group’.
Table 1: Demographic data
Factor Group S Group X p-value
Mean age in years 
(95% CI)
44.1 ± 15.8  
(CI95% 39.8–48.8)
43.4 ± 15.6  
(CI95% 39.1–47.7)
0.819
Gender (% male) 40% 28% 0.205
Table 2: Pain scores
 Group n Median 95% CI Interquartile range Range p-value
Group S 50 4 3–5 3–5 0–10 0.001*
Group X 50 2 2–3 1–4 0–7
Figure 1: Pain score data.
Pain score ranges and medians with 95% CI.
Figure 2: Pain categories.
Graph of the percentage of patients within each pain category for the saline (S) 
and Xylocaine® (X) groups. Pain categorisation: 0 (nil), 1–4 (mild), 5–7 (moderate) 
and 8–10 (severe)
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Techniques previously investigated to ameliorate venepuncture 
pain have included gaze aversion, hypnosis, music distraction, 
performing a Valsalva manoeuvre, administering oral sucrose 
solutions to children, local application of cold using ethyl 
chloride, local capsaicin application, subcutaneous local 
anaesthetic infiltration, and topical local anaesthetic.8,9
Subcutaneous local anaesthetic infiltration typically elicits a VAS 
score of 1–2, significantly less painful than intravenous 
cannulation.10 Nonetheless, many physicians still eschew its use, 
rationalising that it replaces one painful needling procedure 
with another, causes subcutaneous skin distortion and more 
difficult cannula siting. In addition, lack of drug and equipment, 
particularly in wards, impedes its use.11
Lignocaine has a low molecular weight (234.34 Dalton), high 
lipid-solubility and high pKa (7.8) with consequently a high un-
ionised fraction at physiological pH. These physico-chemical 
properties facilitate rapid lipid membrane penetration and onset 
of cutaneous anaesthesia once the sub-epidermal nerve endings 
have been reached.12–14 However, cutaneously applied lignocaine 
must first cross the relatively impermeable stratum corneum, a 
teleological defence barrier. Its impermeability can be attributed 
to its specific structure, consisting of a cornified proteinaceous 
envelope surrounding keratin-containing corneocytes 
interspersed by extracellular lipid lamellae.15
A recurring theme is how to facilitate transfer of topical lignocaine 
across the stratum corneum.16−20 Mechanisms to enhance drug 
transfer across the stratum corneum include using a high drug 
concentration, the addition of solvent vehicles or penetration 
enhancers (e.g. water, ethanol, polyethylene glycol) or the 
application of an occlusive dressing over the treated skin area.17 
Both the addition of water and the use of an occlusive dressing 
serve to hydrate the skin. It is unclear exactly how cutaneous 
hydration enhances drug penetration. Postulated mechanisms 
include equilibration of the water content of the stratum 
corneum and dermis, or that water saturation disrupts the 
stratum corneum’s lipid bilayer. Both ethanol and polyethylene 
glycol probably enhance drug transfer by altering the solvent 
properties of tissue.18 Ethanol is thought to cause fluidisation of 
intercellular lipids.19,20 Interestingly, Xylocaine® 10% Pump Spray 
contains 24.1% m/v ethanol 95%, polyethylene glycol 400 and 
purified water. Xylocaine® 10% Pump Spray’s formulation and its 
application using an occlusive dressing fulfils many of the 
aforementioned criteria to enhance cutaneous drug transfer.
Despite previous research indicating effective blunting of dermal 
perception of electrical current and the skin-penetrating 
attributes of Xylocaine® 10% Pump Spray, it has still been used 
almost exclusively for mucous membrane analgesia.2 To our 
knowledge, no previous study has investigated its ability to 
reduce venepuncture pain.
Two commercially available topical preparations are used for 
ameliorating venepuncture pain. EMLA® (eutectic mixture of 
2.5% lignocaine and 2.5% prilocaine) is an oil-in-water emulsion 
containing a high concentration of 20% lignocaine within each 
emulsion droplet. The low overall concentration (5% lignocaine) 
of local anaesthetic, however, carries a low risk of toxicity.21 
EMLA® provides excellent analgesia when applied for 1 h prior 
to venepuncture.22 Amethocaine topical gel (Ametop 4%, Smith 
& Nephew, Hull, England) requires a 30–45 min application time 
to be effective. A Cochrane systematic review reported 
amethocaine topical gel to be more effective than EMLA® at 
reducing venepuncture pain. It is not currently available in 
South Africa.23
In this initial study, we elected to simply compare Xylocaine® 
Pump Spray with a placebo, and will in the future need to 
compare it directly with EMLA®. EMLA® needs to be applied 1 h 
prior to the needling procedure to be effective.22 Our study 
indicated that Xylocaine® 10% Pump Spray was effective after 
only 20 min. We did not compare directly with EMLA® or 
amethocaine gel but the short application time needed may 
enable a greater percentage of patients to receive topical local 
anaesthesia prior to venous cannulation. It would be interesting 
to investigate the speed of onset of alkalinised topical lignocaine.
Mucous membrane application yields the highest serum 
concentrations after topical lignocaine application.24 Despite the 
use of high lignocaine concentrations (8–10%), dermal 
application appears safe. Even after Xylocaine® 10% topical spray 
(70.3 ± 23.3 mg) was applied to broken skin, serum levels were 
still 25 times lower than the toxic concentration of 5 µg/ml.3 We 
would expect very low serum lignocaine concentrations 
following the cutaneous application of a gauze pad impregnated 
with only 50 mg of lignocaine. Nonetheless, we would need to 
measure serum lignocaine concentrations before we could 
perform a similar study in children.
Ametop is not available in South Africa. Single applications of 1 g 
of EMLA® and Xylocaine® spray at the dose used in this study 
would amount to a cost of R6.90 and R1.05, respectively. This 
equates to an 86% cost reduction by using Xylocaine® instead of 
EMLA®. The cost of the plastic dressing remains the same in both 
instances.
Our study indicates that 10% Xylocaine® spray would potentially 
provide a rapidly effective, readily available, cheaper alternative 
to blunt venepuncture pain.
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Figure 3: Dichotomisation of pain scores.
Percentage of patients in saline (S) and Xylocaine® (X) groups after 
dichotomisation of the pain scores into ‘nil-to-mild’ (Numerical Rating Scale 0–4) 
and ‘moderate-to-severe’ pain (Numerical Rating Scale 5–10); p = 0.009.
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